Biosimilars, like their innovator products, are biologic agents in which the active drug is produced by or derived from a living organism, usually accomplished by gene expression or recombinant DNA techniques. How these agents are ultimately named affects multiple elements of their use including safety, tracking, billing, promotion, and information dissemination. Several strategies for product naming are discussed. The importance of patient safety is emphasized as the overriding concern. Manufacturers, patients, as well as government, and professional organizations are called upon to work together to reach a final solution that is supported by comprehensive programs for education and awareness programs covering how best to prescribe, dispense and use these products.